ART-related lactic acidosis, hyperlactataemia, peripheral neuropathy, lipodystrophy, hepatic steatosis and pancreatitis 7 are thought to result from mitochondrial dysfunction due to nucleoside reverse transcriptase inhibitors (NRTIs) interfering with human mitochondrial DNA polymerase g enzyme activity.
Introduction
South Africa has one of the highest human immunodeficiency virus (HIV) prevalence globally (11% in 2008). KwaZuluNatal is the worst affected province (16%). 1 Drug toxicity is a major challenge when prescribing antiretroviral therapy (ART). Recent studies in South Africa reported incidence rates of lactic acidosis of 11-19 per 1 000 person-years, [2] [3] [4] higher than the 0.6-10 per 1 000 person-years reported in high-income countries. S Afr Fam Pract 2014 18 months). [2] [3] [4] Other drug-induced toxic effects, such as peripheral neuropathy and lipodystrophy, and a raised alanine transaminase (ALT), have been associated with the development of lactic acidosis. 3, 9 Recent controlled studies provide conflicting evidence with regard to other risk factors for lactic acidosis, such as increased age, impaired renal function, low serum albumin and a low CD4 count. 3, 10 The first objective of this study was to describe the demographic, clinical and biochemical features of persons presenting with lactic acidosis. The subsequent objective was to determine the clinical and laboratory factors that might predict the development of lactic acidosis prior to commencement of ART, and while on ART (early warning signs), and therefore define a category of patients at particular risk of developing lactic acidosis.
Method

Setting
The study was conducted at Port Shepstone Hospital in KwaZulu-Natal, which serves a semi-rural population. Adult persons living with HIV with a CD4 count less than 200 cells/µl, or World Health Organization stage 4 disease (acquired immune deficiency syndrome-defining criteria) routinely received twice-daily stavudine 40 mg if they weighed over 60 kg, or 30 mg if they weighed less than 60 kg up to July 2007, after which all patients received 30 mg combined with lamivudine and either nevirapine or efavirenz. Zidovudine was usually substituted for stavudine when severe stavudine toxicity occurred. The investigations were performed at an on-site laboratory, excepting the HIV viral load estimations.
Study design
The incidence and nature of stavudine toxicity was described using a retrospective cohort of persons living with HIV (> 18 years) commenced on stavudine-containing ART from July 2004 to April 2007, and followed until November 2008. A matched case control study was nested within this cohort to determine the risk factors for lactic acidosis.
Cases
Lactic acidosis cases had to have completed at least four months of ART and to have presented with symptoms of hyperlactataemia (unexplained weight loss, loss of appetite, abdominal pain, abdominal distension, nausea or shortness of breath). Serum lactate had to be ≥ 5 mmol/l and serum CO 2 or standard bicarbonate (SHCO 3 ) < 20 mmol/l. 2, 3, 10 If the lactate was above normal (> 2.5 mmol/l), but did not fulfil the biochemical criteria for lactic acidosis, then a diagnosis of symptomatic hyperlactataemia was made. Potential lactic acidosis cases who also had another possible cause of lactic acidosis, such as diabetic ketoacidosis, dehydration, sepsis and renal failure, were excluded.
Controls
Controls had to have completed at least 15 months of ART, and not to have developed any stavudine-related toxicity that required its discontinuation. Controls were matched with lactic acidosis cases according to the period of ART commencement to ensure equal duration of drug exposure. 3 This also reduced bias that might have been caused by the evolving state of knowledge on the diagnosis and management of stavudine-induced lactic acidosis.
Data collection and analysis
Baseline data were extracted from the hospital's electronic register. Cases presenting with stavudine-induced lactic acidosis were identified from pharmacy, admission and mortuary records. A retrospective chart review was performed on all cases and controls.
Statistical analysis
Conditional logistic regression modelling was used to compare exposure variables between cases and controls. Analysis was controlled for weight and gender. A p-value of < 0.05 was considered to be significant. Approval was obtained from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal, the provincial Department of Health and hospital management. 
Results
Description of entire cohort
Incidence of stavudine toxicity
Stavudine-induced toxicity requiring a drug substitution occurred in 275 (60 per 1 000 person-years) persons with HIV and commenced on ART. Lactic acidosis occurred in 79 (17 per 1 000 person-years). The highest incidence was females > 90 kg (109 per 1 000 person-years) ( Table II) .
Spectrum of clinical presentation and mortality of lactic acidosis
In the 63 cases with lactic acidosis and complete records, 59 (94%) presented with weight loss (a median loss of 6 kg, interquartile range of 4-8 kg), 45 (71%) with abdominal symptoms (nausea, anorexia, pain or distension), 15 (24%) with peripheral oedema and 8 (13%) with dyspnoea. Peripheral neuropathy was recorded in 44 (56%) and lipodystrophy in 35 (42%) cases. Weight loss was the only presenting symptom in 13 (21%) and a combination of weight loss and abdominal symptoms occurred in 43 (68%) cases. Lactic acidosis took place after between eight S Afr Fam Pract 2014 and 16 months' treatment duration in the majority (67/79, 85%) of cases (a median of 10 months, and a range of 5-24 months).
The median serum lactate was 7.5 mmol/l (a range of 5-11.7), and mean serum CO 2 of 17 (a range of 0-19), of which 21 of 79 (27%) had lactate > 10 mmol/l or serum CO 2 < 15 mmol/l). In a subgroup of 65 cases who had a blood gas analysis, 49 (75%) had a pH < 7.34 and 11 (17%) a pH < 7.2.
Overall mortality from lactic acidosis was 7.6% (6/79). The cases who died had a lactate of > 10 mmol/l. Of the patients with lactate > 10, 40% (6/15, 40%) died. Seventy-five per cent (6/8) of cases with a serum CO 2 < 15 mmol died. All of the cases with a serum CO 2 < 10 mmol/l died. Fifty-five per cent (6/11) of patients with a pH < 7.2 and 83% (5/6) with a pH < 7.1 died. Four cases of lactic acidosis occurred during pregnancy. All of these patients survived. Three pregnancies were carried to term. The babies were born alive and well. There was one intrauterine death.
Patients with stavudine toxicity were changed from stavudine to zidovudine without recurrence of lactic acidosis during the follow-up period.
Comparison between lactic acidosis cases and controls at baseline
The clinical characteristics of cases with lactic acidosis and matched controls were compared at baseline (Table III) . Female gender and weight were the only two parameters that emerged to have a statistically significant difference. As the baseline weight category of cases increased from < 60 kg, the risk of developing lactic acidosis increased significantly. When the weight increased to 60-69 kg, 
Comparison of cases and controls six months after commencement of antiretroviral therapy
The clinical characteristics and associations between cases with lactic acidosis and matched controls were again compared six months into ART (Table IV) . Higher ALT or triglycerides (TGs) were significantly associated with lactic acidosis. ALT was > 50 IU/l in 30% of cases, compared to only 9% of controls. Sixty-eight per cent of cases (19/28) with an ALT > 35 IU/l presented before 11 months on ART, compared to 35% (9/26) after 11 months (OR 3.4, p-value 0.034).
The risk (OR adjusted for weight and gender) of a case versus a control having a TG level at six months (exposure) of 0.5-1 mmol/l, 1.1-1.5 mmol/l and > 1.5 mmol/l, relative to those with TG < 1 mmol/l, were 3.9 (95% CI: 0.7-21.3, p-value 0.117), 11.2 (95% CI: 1.1-118.6, p-value 0.043) and 4.9 (95% CI: 0.2-103.2, p-value 0.311), respectively. There was no correlation between the ALT and TGs (Spearman's rank correlation coefficient 0.083, p-value 0.372).
Discussion
In this study, we confirmed the increased incidence of stavudine-induced lactic acidosis in South Africa, better defined associated risk factors, and also proposed laboratory markers that may have the potential to help to predict lactic acidosis.
Baseline risk factors
This study confirmed female gender and a high body weight to be strong risk factors for lactic acidosis (Table III) . [2] [3] [4] The relationship with weight, particularly in females, appears to be complex (Table II) . A sudden increase in incidence was observed when the baseline weight exceeded 60 kg, followed by an exponential increase when the baseline weight was more than 80 kg. It could be postulated that the first increase in incidence was attributed to the escalation in the dose of stavudine since it coincided with the recommended dose adjustment at 60 kg, and also because mitochondrial toxicity has been shown to be dose related. 9 The further increasing incidence above 80 kg, although the numbers were small in the higher-weight categories, was consistent with other studies, 10 and is likely to be owing to other weight-related factors.
Other factors considered to confer increased risk of developing lactic acidosis, such as age, CD4 count, renal function and albumin levels, did not emerge as risk factors in our study. Our findings were in keeping with others in the literature. 3 The consistently higher incidence of lactic acidosis in developing countries compared to that in high-income countries remains an enigma. Possible explanations include the fact that females are markedly under-represented in in high-income country studies (26% in the Swiss cohort study), 11 and that female obesity is less common in such countries 12 compared to South Africa. 13 Encouraging patients in South Africa to tolerate other stavudine-related toxic effects owing to limited treatment alternatives may have facilitated further mitochondrial toxicity to the extent that lactic acidosis developed. This is supported by a high percentage of lactic acidosis cases in which other manifestations of mitochondrial toxicity were present. Other factors to be considered are genetic and the use of herbal medication which may potentiate stavudine toxicity directly or through drug interactions.
The predictive value of laboratory markers six months into antiretroviral therapy Considering the late onset of lactic acidosis, which was confirmed in this study to occur between six and 18 months, 3 laboratory marker risk indicators, which are only apparent at six months into ART, may serve as useful and timely flags. This study showed that even after adjustment for gender and weight, ALT and TG levels at six months were significantly higher in cases (Table IV) . The rise in ALT may be a manifestation of early stavudine-induced steatohepatitis. 3, 6 This was underscored by the fact that patients with raised ALT at six months tended to present sooner with lactic acidosis.
The increased risk of lactic acidosis in patients with elevated TGs at six months, albeit within the normal range (Table  IV) , was not surprising when it is considered that elevated TGA levels have been associated with hyperlactataemia. 14 It was of interest that there was no correlation between the increase in ALT and TG levels. These findings need confirmation and further study by other investigators.
Mortality and early lactic acidosis identification
The mortality in this study was unusually low. This may be ascribed to enhanced clinical vigilance with the early detection of lactic acidosis. Weight monitoring appeared to be useful. The recognised associations of mortality, such as the level of lactate and severity of metabolic disturbance upon presentation, were also observed here.
Limitations of the study
As this was a retrospective study, we had to contend with incomplete recordkeeping. Body mass index could not be calculated since height was not measured.
Conclusion and recommendations
This study confirms the increased risk of lactic acidosis in patients on stavudine in a resource-limited setting. Obese females are at greatest risk. The 30-mg dose may be preferable given that efficacy has been demonstrated at lower doses. 15 Additional risk factors for lactic acidosis include high ALT and TG levels at treatment, but this needs further evaluation. The presence of other stavudine-related toxicities and weight loss might predict increased risk or onset of lactic acidosis.
